(Circulation. 1999;99:1776-1779.)
© 1999 American Heart Association, Inc.
Brief Rapid Communications |
Adenovirus-Mediated Delivery of Fas Ligand Inhibits Intimal Hyperplasia After Balloon Injury in Immunologically Primed Animals
From the Division of Cardiovascular Research, St Elizabeth's Medical Center, Tufts University School of Medicine, Boston, Mass (Z.L., M.S., T.N., K.W.), and Genzyme Corp, Framingham, Mass (J.M.K, G.Y.A).
Correspondence to Dr Kenneth Walsh, Division of Cardiovascular Research, St Elizabeth's Medical Center, 736 Cambridge St, Boston, MA 02135. E-mail kwalsh{at}opal.tufts.edu
Abstract
Background—Adenoviral constructs have been used for studies of injury-induced vascular hyperplasia in immunologically naive laboratory animals, but their usefulness for intra-arterial gene therapy may be limited by the prevalence of preexisting immunity to adenovirus in the patient population. Here, we explored the efficacy of adenovirus-mediated transfer of Fas ligand, a cytotoxic gene with immunomodulatory properties, in inhibiting injury-induced vascular lesion formation in both naive and immunologically primed animals.
Methods and Results—Lesion formation was evaluated in balloon-injured carotid arteries of naive and adenovirus-immunized rats that were infected with adenoviral constructs expressing Fas ligand (Ad-FasL), the cyclin-dependent kinase inhibitor p21 (Ad-p21), or ß-galactosidase (Ad-ßgal). In naive rats, Ad-FasL induced apoptosis in medial vascular smooth muscle cells and inhibited intimal hyperplasia by 60% relative to Ad-ßgal–treated vessels (P<0.05), whereas the cytostatic agent Ad-p21 decreased lesion size by 58% (P<0.05). In animals preimmunized with an adenoviral vector containing no transgene, Ad-FasL significantly inhibited neointima formation (73% reduction, P<0.05), but Ad-p21 failed to inhibit neointima formation relative to controls. Immunologically primed rats displayed robust T-cell infiltration in Ad-p21– and Ad-ßgal–treated vessels, but T-cell infiltration was markedly attenuated in Ad-FasL–treated vessels.
Conclusions—Our data demonstrate that adenovirus-mediated Fas ligand delivery can inhibit intimal hyperplasia in both immunologically primed and naive animals, whereas the efficacy of an adenovirus-mediated p21 delivery is limited to immunologically naive animals. This study documents, for the first time, the therapeutic efficacy of intravascular adenoviral gene transfer in animals with preexisting immunity to adenovirus.
Key Words: restenosis • genes • viruses • lymphocytes
This article has been cited by other articles:
 |
|
 |
|
  M. M. Kavurma, N. Y. Tan, and M. R. Bennett Death Receptors and Their Ligands in Atherosclerosis Arterioscler Thromb Vasc Biol, October 1, 2008; 28(10): 1694 - 1702. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Chen, C. Wasserfall, M. H. Kapturczak, M. Atkinson, and A. Agarwal Freeze-thaw increases adeno-associated virus transduction of cells Am J Physiol Cell Physiol, August 1, 2006; 291(2): C386 - C392. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Matter, C. E. Chadjichristos, P. Meier, T. von Lukowicz, C. Lohmann, P. K. Schuler, D. Zhang, B. Odermatt, E. Hofmann, T. Brunner, et al. Role of Endogenous Fas (CD95/Apo-1) Ligand in Balloon-Induced Apoptosis, Inflammation, and Neointima Formation Circulation, April 18, 2006; 113(15): 1879 - 1887. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Lim, C. J. Jin, M. Kim, S. S. Chung, H. S. Park, I. K. Lee, C. T. Lee, Y. M. Cho, H. K. Lee, and K. S. Park PPAR{gamma} Gene Transfer Sustains Apoptosis, Inhibits Vascular Smooth Muscle Cell Proliferation, and Reduces Neointima Formation After Balloon Injury in Rats Arterioscler Thromb Vasc Biol, April 1, 2006; 26(4): 808 - 813. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K.-i. Kim, H.-J. Cho, J.-Y. Hahn, T.-Y. Kim, K.-W. Park, B.-K. Koo, C. Soo Shin, C.-H. Kim, B.-H. Oh, M.-M. Lee, et al. {beta}-Catenin Overexpression Augments Angiogenesis and Skeletal Muscle Regeneration Through Dual Mechanism of Vascular Endothelial Growth Factor-Mediated Endothelial Cell Proliferation and Progenitor Cell Mobilization Arterioscler Thromb Vasc Biol, January 1, 2006; 26(1): 91 - 98. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Wessely Interference by interferons: Janus faces in vascular proliferative diseases Cardiovasc Res, June 1, 2005; 66(3): 433 - 443. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Yang, K. Sato, T. Aprahamian, N. J. Brown, J. Hutcheson, A. Bialik, H. Perlman, and K. Walsh Endothelial Overexpression of Fas Ligand Decreases Atherosclerosis in Apolipoprotein E-Deficient Mice Arterioscler Thromb Vasc Biol, August 1, 2004; 24(8): 1466 - 1473. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Aprahamian, I. Rifkin, R. Bonegio, B. Hugel, J.-M. Freyssinet, K. Sato, J. J. Castellot Jr., and K. Walsh Impaired Clearance of Apoptotic Cells Promotes Synergy between Atherogenesis and Autoimmune Disease J. Exp. Med., April 19, 2004; 199(8): 1121 - 1131. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Yang, S. P. Jones, T. Suhara, J. J. M. Greer, P. D. Ware, N. P. Nguyen, H. Perlman, D. P. Nelson, D. J. Lefer, and K. Walsh Endothelial Cell Overexpression of Fas Ligand Attenuates Ischemia-Reperfusion Injury in the Heart J. Biol. Chem., April 18, 2003; 278(17): 15185 - 15191. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Sata, A. Takahashi, K. Tanaka, M. Washida, N. Ishizaka, J. Ako, M. Yoshizumi, Y. Ouchi, T. Taniguchi, Y. Hirata, et al. Mouse Genetic Evidence That Tranilast Reduces Smooth Muscle Cell Hyperplasia via a p21WAF1-Dependent Pathway Arterioscler Thromb Vasc Biol, August 1, 2002; 22(8): 1305 - 1309. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. S. Zuckerbraun and E. Tzeng Vascular Gene Therapy: A Reality of the 21st Century Arch Surg, July 1, 2002; 137(7): 854 - 861. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Suhara, H.-S. Kim, L. A. Kirshenbaum, and K. Walsh Suppression of Akt Signaling Induces Fas Ligand Expression: Involvement of Caspase and Jun Kinase Activation in Akt-Mediated Fas Ligand Regulation Mol. Cell. Biol., January 15, 2002; 22(2): 680 - 691. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Sata, S. Sugiura, M. Yoshizumi, Y. Ouchi, Y. Hirata, and R. Nagai Acute and Chronic Smooth Muscle Cell Apoptosis After Mechanical Vascular Injury Can Occur Independently of the Fas-Death Pathway Arterioscler Thromb Vasc Biol, November 1, 2001; 21(11): 1733 - 1737. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Belanger, A. Scaria, H. Lu, J. A. Sullivan, S. H. Cheng, R. J. Gregory, and C. Jiang Fas ligand/Fas-mediated apoptosis in human coronary artery smooth muscle cells: therapeutic implications of fratricidal mode of action Cardiovasc Res, September 1, 2001; 51(4): 749 - 761. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Sata, Z. Luo, and K. Walsh Fas Ligand Overexpression on Allograft Endothelium Inhibits Inflammatory Cell Infiltration and Transplant-Associated Intimal Hyperplasia J. Immunol., June 1, 2001; 166(11): 6964 - 6971. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Krick, O. Platoshyn, M. Sweeney, H. Kim, and J. X.-J. Yuan Activation of K+ channels induces apoptosis in vascular smooth muscle cells Am J Physiol Cell Physiol, April 1, 2001; 280(4): C970 - C979. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Hall, C. M. Matter, X. Wang, and G. H. Gibbons Hyperglycemia Inhibits Vascular Smooth Muscle Cell Apoptosis Through a Protein Kinase C-Dependent Pathway Circ. Res., September 29, 2000; 87(7): 574 - 580. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Walsh, R. C. Smith, and H.-S. Kim Vascular Cell Apoptosis in Remodeling, Restenosis, and Plaque Rupture Circ. Res., August 4, 2000; 87(3): 184 - 188. [Full Text] [PDF]
|
|
|
|
|
|
M. R. Kibbe, T. R. Billiar, and E. Tzeng Gene Therapy for Restenosis Circ. Res., April 28, 2000; 86(8): 829 - 833. [Full Text] [PDF]
|
|
|
|
|
|
D. B. Schneider, G. Vassalli, S. Wen, R. M. Driscoll, A. B. Sassani, M. B. DeYoung, R. Linnemann, R. Virmani, and D. A. Dichek Expression of Fas Ligand in Arteries of Hypercholesterolemic Rabbits Accelerates Atherosclerotic Lesion Formation Arterioscler Thromb Vasc Biol, February 1, 2000; 20(2): 298 - 308. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Sata, T. Suhara, and K. Walsh Vascular Endothelial Cells and Smooth Muscle Cells Differ in Expression of Fas and Fas Ligand and in Sensitivity to Fas Ligand-Induced Cell Death : Implications for Vascular Disease and Therapy Arterioscler Thromb Vasc Biol, February 1, 2000; 20(2): 309 - 316. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Walsh and J. M. Isner Apoptosis in inflammatory-fibroproliferative disorders of the vessel wall Cardiovasc Res, February 1, 2000; 45(3): 756 - 765. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Sinnaeve, O. Varenne, D. Collen, and S. Janssens Gene therapy in the cardiovascular system: an update Cardiovasc Res, December 1, 1999; 44(3): 498 - 506. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M. Kavurma, F. S. Santiago, E. Bonfoco, and L. M. Khachigian Sp1 Phosphorylation Regulates Apoptosis via Extracellular FasL-Fas Engagement J. Biol. Chem., February 9, 2001; 276(7): 4964 - 4971. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. C. FRANCIS, M. K. RAIZADA, A. A. MANGI, L. G. MELO, V. J. DZAU, P. R. VALE, J. M. ISNER, D. W. LOSORDO, J. CHAO, M. J. KATOVICH, et al. Genetic targeting for cardiovascular therapeutics: are we near the summit or just beginning the climb? Physiol Genomics, December 21, 2001; 7(2): 79 - 94. [Abstract] [Full Text] [PDF]
|
|